Plain-English translation of NCT03495024 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Schizophrenia research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether , an FDA-approved medication to help people quit smoking, can work safely and effectively in people with schizophrenia or schizoaffective disorder. Researchers want to learn if quitting smoking with this medication might also reduce certain movement-related side effects that some people experience from their antipsychotic medications. This is a small pilot study with 10 participants over 12 weeks.
People with schizophrenia smoke at much higher rates than the general population, which puts them at greater risk for serious health problems. Some research suggests that nicotine in cigarettes may actually worsen certain medication side effects, so researchers want to know if helping these patients quit smoking could improve both their overall health and reduce bothersome symptoms.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic 7 times over 12 weeks. After an initial screening visit, you would start taking the medication at a low dose that gradually increases over the first week. Your goal is to quit smoking completely by week 6. At each visit, researchers will check how you're doing with quitting, measure the carbon monoxide in your breath to verify smoking status, and assess any changes in your movement-related symptoms using standardized rating scales. The visits take place at weeks 0, 2, 3, 6, 8, 10, and 12.
AI-generated summary from trial data · Jul 2, 2026 · Not medical advice
United States